Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 3/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CNR2 | P34972 | 2/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 5/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 4/20 | 0.42 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.42 |
| ▸ | VDR | P11473 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL709198 | 0.87 | CYP1A2 (0.52) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL9159670 | 0.85 | CYP1A2 (0.56) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL6432354 | 0.82 | ADRB2 (0.61) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL10417450 | 0.80 | CYP1A2 (0.60) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL24782977 | 0.79 | SLC2A1 (0.48) | MEN1KMT2ALMNACNR2SLC2A1 | |
| SCHEMBL25776518 | 0.79 | SLC2A1 (0.58) | CYP1A2MEN1CYP2C19KMT2ALMNA | |
| SCHEMBL15663208 | 0.77 | KDM4E (0.43) | CYP1A2KDM4EMEN1CYP2C19KMT2A | |
| SCHEMBL9650074 | 0.76 | CNR2 (0.55) | MEN1KMT2ACNR2ADRB2ADRB1 | |
| SCHEMBL9652151 | 0.76 | HTT (0.50) | KDM4EMEN1KMT2ALMNACNR2 | |
| SCHEMBL28769919 | 0.75 | SLC2A1 (0.57) | CYP1A2MEN1CYP2C19KMT2ACNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8575176-B2 | Heteroaromatic pyrazinoylguanidine sodium channel blockers | PARION SCIENCES, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | PARION SCIENCES, INC. (US) | 2012-05-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120116083-A1 | HETEROAROMATIC PYRAZINOYLGUANIDINE SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, KCNH1 | CYP1A2 416/4885KDM4E 3151/4885MEN1 2048/4885 |
| US-20140031371-A1 | POLY AROMATIC SODIUM CHANNEL BLOCKERS | HCN4, SCN2B, SCNN1B | CYP1A2 745/4885KDM4E 2068/4885MEN1 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.